| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
ID: ALA4173493
Max Phase: Preclinical
Molecular Formula: C19H23ClN4O4S
Molecular Weight: 438.94
Molecule Type: Small molecule
Associated Items:
Representations
Canonical SMILES: COCCOc1cc2ncc(-c3cc(N)nc(Cl)c3)n2cc1S(=O)(=O)C(C)(C)C
Standard InChI: InChI=1S/C19H23ClN4O4S/c1-19(2,3)29(25,26)15-11-24-13(12-7-16(20)23-17(21)8-12)10-22-18(24)9-14(15)28-6-5-27-4/h7-11H,5-6H2,1-4H3,(H2,21,23)
Standard InChI Key: DCAJEEHUEYUYHB-UHFFFAOYSA-N
Associated Targets(Human)
RIPK2 Tchem Serine/threonine-protein kinase RIPK2 (1546 Activities)
MAPK3 Tchem Mitogen-activated protein kinase; ERK1/ERK2 (651 Activities)
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
MAPK13 Tchem MAP kinase p38 (1586 Activities)
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
RPS6KA3 Tchem Ribosomal protein S6 kinase (115 Activities)
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
Associated Targets(non-human)
Mus musculus (284745 Activities)
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
Ripk2 Receptor-interacting serine/threonine-protein kinase 2 (5 Activities)
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
Ripk2 Receptor-interacting serine/threonine-protein kinase 2 (6 Activities)
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
Molecule Features
| Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
| Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
| Chirality: No | Availability: No | Prodrug: No |
Drug Indications
| MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
|---|
Mechanisms of Action
| Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
|---|
Properties
| Molecular Weight: 438.94 | Molecular Weight (Monoisotopic): 438.1129 | AlogP: 3.23 | #Rotatable Bonds: 6 |
| Polar Surface Area: 108.81 | Molecular Species: NEUTRAL | HBA: 8 | HBD: 1 |
| #RO5 Violations: 0 | HBA (Lipinski): 8 | HBD (Lipinski): 2 | #RO5 Violations (Lipinski): 0 |
| CX Acidic pKa: | CX Basic pKa: 4.81 | CX LogP: 1.85 | CX LogD: 1.84 |
| Aromatic Rings: 3 | Heavy Atoms: 29 | QED Weighted: 0.46 | Np Likeness Score: -0.90 |
References
| 1. He X, Da Ros S, Nelson J, Zhu X, Jiang T, Okram B, Jiang S, Michellys PY, Iskandar M, Espinola S, Jia Y, Bursulaya B, Kreusch A, Gao MY, Spraggon G, Baaten J, Clemmer L, Meeusen S, Huang D, Hill R, Nguyen-Tran V, Fathman J, Liu B, Tuntland T, Gordon P, Hollenbeck T, Ng K, Shi J, Bordone L, Liu H.. (2017) Identification of Potent and Selective RIPK2 Inhibitors for the Treatment of Inflammatory Diseases., 8 (10): [PMID:29057049] [10.1021/acsmedchemlett.7b00258] |
Source
Source(1):